C
Christopher S. Coffey
Researcher at University of Iowa
Publications - 197
Citations - 16546
Christopher S. Coffey is an academic researcher from University of Iowa. The author has contributed to research in topics: Randomized controlled trial & Sample size determination. The author has an hindex of 52, co-authored 187 publications receiving 13716 citations. Previous affiliations of Christopher S. Coffey include University of Alabama at Birmingham & Vanderbilt University.
Papers
More filters
Journal ArticleDOI
2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.
William J. Powers,Colin P. Derdeyn,José Biller,Christopher S. Coffey,Brian L. Hoh,Edward C. Jauch,Karen C. Johnston,S. Claiborne Johnston,Alexander A. Khalessi,Chelsea S. Kidwell,James F. Meschia,Bruce Ovbiagele,Dileep R. Yavagal +12 more
TL;DR: In this article, a focused update of the current recommendations for the endovascular treatment of acute ischemic stroke is provided, where the recommendations made here supersede those of previous guidelines when there is overlap.
Journal ArticleDOI
Predicting Survival in Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
Raymond L. Benza,Dave P. Miller,Mardi Gomberg-Maitland,Robert P. Frantz,Aimee J. Foreman,Christopher S. Coffey,Adaani E. Frost,Robyn J. Barst,David B. Badesch,C. Gregory Elliott,Theodore G. Liou,Michael D. McGoon +11 more
TL;DR: This work identified key predictors of survival based on the patient's most recent evaluation and formulated a contemporary prognostic equation that may allow the individualization and optimization of therapeutic strategies.
Journal ArticleDOI
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek,Danna Jennings,Shirley Lasch,Andrew Siderowf,Caroline M. Tanner,Tanya Simuni,Christopher S. Coffey,Karl Kieburtz,Emily Flagg,Sohini Chowdhury,Werner Poewe,Brit Mollenhauer,Todd Sherer,Mark Frasier,Claire Meunier,Alice Rudolph,Cindy Casaceli,John Seibyl,Susan Mendick,Norbert Schuff,Ying Zhang,Arthur W. Toga,Karen Crawford,Alison Ansbach,Pasquale De Blasio,Michele Piovella,John Q. Trojanowski,Les Shaw,Andrew B. Singleton,Keith A. Hawkins,Jamie L. Eberling,David W. Russell,Laura Leary,Stewart A. Factor,Barbara Sommerfeld,Penelope Hogarth,Emily Pighetti,Karen Williams,David G. Standaert,Stephanie Guthrie,Robert A. Hauser,Holly Delgado,Joseph Jankovic,Christine Hunter,Matthew B. Stern,Baochan Tran,James B. Leverenz,Marne Baca,Sam Frank,Cathi A. Thomas,Irene H. Richard,Cheryl Deeley,Linda Rees,Fabienne Sprenger,Elisabeth Lang,Holly A. Shill,Sanja Obradov,Hubert H. Fernandez,Adrienna Winters,Daniela Berg,Katharina Gauss,Douglas Galasko,Deborah Fontaine,Zoltan Mari,Melissa Gerstenhaber,David J. Brooks,Sophie Malloy,Paolo Barone,Katia Longo,Tom Comery,Bernard Ravina,Igor D. Grachev,Kim Gallagher,Michelle Collins,Katherine Widnell,Suzanne Ostrowizki,Paulo Fontoura,F. Hoffmann La-Roche,Tony W. Ho,Johan Luthman,Marcel P. van der Brug,Alastair D. Reith,Peggy Taylor +82 more
TL;DR: The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials.
Journal ArticleDOI
Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.
Oscar R. Benavente,Christopher S. Coffey,Robin Conwit,Robert G. Hart,Leslie A. McClure,Lesly A. Pearce,Pablo E. Pergola,Jeff M. Szychowski +7 more
TL;DR: Although the reduction in stroke was not significant, the results support that in patients with recent lacunar stroke, the use of a systolic-blood-pressure target of less than 130 mm Hg is likely to be beneficial.
Journal ArticleDOI
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
Sps investigators,Oscar R. Benavente,Robert G. Hart,Leslie A. McClure,Jeff M. Szychowski,Christopher S. Coffey,Lesly A. Pearce +6 more
TL;DR: Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase therisk of bleeding and death.